TRAILR1/TNFRSF10A Antibody (32A1380) - BSA Free

Western Blot: TRAIL R1/TNFRSF10A Antibody (32A1380) [NB100-56747] - Analysis of DR4 in Daudi cell lysate using DR4 antibody at 2 ug/ml. Goat anti-mouse Ig HRP secondary antibody and PicoTect ECL substrate solution were used for this test.

Simple Western: TRAIL R1/TNFRSF10A Antibody (32A1380) [NB100-56747] - Simple Western lane view shows a specific band for TRAIL R1 in 0.5 mg/ml of Daudi lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system. * Non-specific interaction with the 230 kDa Simple Western standard may be seen with this antibody

• Reactivity: Hu
• Applications: WB, Simple Western, Flow, ICC/IF, CyTOF-ready
• Clone: 32A1380
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated
• Format: BSA Free
• Concentration: 1.0 mg/ml

TRAILR1/TNFRSF10A Antibody (32A1380) - BSA Free Summary

• Description: Novus Biologicals Mouse TRAILR1/TNFRSF10A Antibody (32A1380) - BSA Free (NB100-56747) is a monoclonal antibody validated for use in WB, Flow, ICC/IF and Simple Western. Anti-TRAILR1/TNFRSF10A Antibody: Cited in 22 publications. All Novus Biologicals antibodies are covered by our 100% guarantee.
• Immunogen: This monoclonal antibody was raised against a peptide corresponding to amino acid 2 to 21 of human DR4.
• Isotype: IgG1 Kappa
• Clonality: Monoclonal
• Host: Mouse
• Gene: TNFRSF10A
• Purity: Protein G purified

Applications/Dilutions

• Dilutions:
  • CyTOF-ready
  • Flow (Cell Surface) reported in scientific literature (PMID 18004565)
  • Flow (Intracellular) reported in scientific literature (PMID 17541421)
  • Flow Cytometry 1:20-1:2000
  • Immunocytochemistry/ Immunofluorescence reported in scientific literature (PMID 26044191)
  • Simple Western 20 ug/mL
  • Western Blot 2-4 ug/ml
• Application Notes: A 57 kDa band should be observed. This antibody is routinely tested by western blot analysis. For other applications, please refer to appropriate published references for more information.
  
  In Simple Western only 10 - 15 ul of the recommended dilution is used per data point.
  See Simple Western Antibody Database for Simple Western validation: Tested in Daudi lysate 0.5 mg/mL, separated by Size, antibody dilution of 20 ug/mL. Separated by Size-Wes, Sally Sue/Peggy Sue. This antibody is CyTOF ready.

Packaging, Storage & Formulations

• Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Buffer: PBS
• Preservative: 0.05% Sodium Azide
• Concentration: 1.0 mg/ml
• Purity: Protein G purified

Alternate Names for TRAILR1/TNFRSF10A Antibody (32A1380) - BSA Free

• APO2
• CD261 antigen
• CD261
• cytotoxic TRAIL receptor
• Death receptor 4
• DR4 TRAIL receptor 1
• DR4
• TNF-related apoptosis inducing ligand receptor 1
• TNF-related apoptosis-inducing ligand receptor 1
• TNFRSF10A
• TRAIL R1
• TRAILR1
• TRAIL-R1
• TRAILR-1
• TRAILR1MGC9365
• tumor necrosis factor receptor superfamily member 10A
• tumor necrosis factor receptor superfamily, member 10a

Background

Cells undergo programmed cell death (Apoptosis) in response to various stimuli. Apoptosis is essential for morphogenesis, tissue homeostasis, and host defense Apoptosis is induced by certain cytokines including TNF and Fas ligand in the TNF family through their death domain containing receptors, TNFR1 and Fas. A novel death domain containing receptor was recently identified and designated DR4 (for death receptor 4). The ligand for this novel death receptor has been identified and termed TRAIL, which is a new member in the TNF family. DR4 is also called TRAIL receptor-1 (TRAIL-R1). DR4 is expressed in most of human tissues including spleen, peripheral blood leukocytes, small intestine and thymus. Like TNFR1, Fas and DR3, DR4 mediates apoptosis and NF-kB activation in many tissues and cells.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for TRAILR1/TNFRSF10A Antibody (NB100-56747)(22)

Publications using NB100-56747

• Chen L, Hao M, Yan J et al. Citrus-derived DHCP inhibits mitochondrial complex II to enhance TRAIL sensitivity via ROS-induced DR5 upregulation The Journal of biological chemistry 2021-03-04 [PMID: 33676890] (FLOW, Human)
• Xue M, Ge Y et al Apoptosis is induced by docosahexaenoic acid in breast cancer cells via death receptor and mitochondria-mediated pathways Mol Med Rep 2017-06-07 [PMID: 28586001] (WB, WB, Human)
  
  Details:
  Citation using the Azide Free version of this antibody.
• Foster KA, Jane EP, Premkumar DR et al. NVP-BKM120 potentiates apoptosis in tumor necrosis factor-related apoptosis-inducing ligand-resistant glioma cell lines via upregulation of Noxa and death receptor 5 Int. J. Oncol. 2015-06-05 [PMID: 26044191] (ICC/IF, Human)
• Qiu F, Hu M, Tang B, Liu X et al. Annexin V-TRAIL fusion protein is a more sensitive and potent apoptotic inducer for cancer therapy. Sci Rep 2013-12-20 [PMID: 24356445] (WB, Human)
• Abdulghani Junaid, Allen Joshua E, Dicker David T et al. Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis. PLoS One. 2013-01-01 [PMID: 24086526] (Human)
• Park S, Cho DH, Andera L et al. Curcumin enhances TRAIL-induced apoptosis of breast cancer cells by regulating apoptosis-related proteins. Mol Cell Biochem 2013-11-01 [PMID: 23846485] (WB, Human)
• Allen JE, Ferrini R, Dicker DT et al. Targeting TRAIL death receptor 4 with trivalent DR4 Atrimer complexes. Mol Cancer Ther. 2012-10-01 [PMID: 22802267]
  
  Details:
  Antibodies cited: 1. DR5 (IMG-120A): Flow (cell surface) 2. DR4 (IMG-141): Flow (cell surface, HCT116 cells), Supplementary Fig. 5. 3. DcR2 (IMG-121-1): WB (SW620 and HCT15 cells), Supplementary Fig. 4.
• Jane EP, Premkumar DR, Pollack IF. Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway. Mol Cancer Ther. 2011-01-01 [PMID: 21220502] (WB)
  
  Details:
  DR4 (IMG-141A) and DR5/TRAILR2 (IMG-120A). WB: Various human glioma cell lines treated with TRAIL: LN18, U87, LNZ308, and U373, Fig 2B & 2C.
• Lin YD, Chen S, Yue P et al. CAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction is a major component of SHetA2-induced apoptosis in lung cancer cells. Cancer Res. 2008-07-01 [PMID: 18593935] (WB)
  
  Details:
  Antibodies cited: [WB ( human non-small cell lung cancer cell lines)]: 1. Anti-caspase-3 (IMG-144A): Figs. 1A,B; 5A. 2. DR4 (NT) TRAIL-R1 (IMG-141A): Figs. 3A.
• Le Poole IC, ElMasri WM, Denman CJ et al. Langerhans cells and dendritic cells are cytotoxic towards HPV16 E6 and E7 expressing target cells. Cancer Immunol Immunother. 2008-06-01 [PMID: 18004565] (Flow - CS, Human)
  
  Details:
  Flow (cell surface), human dendritic cells and langerhans cells, Fig. 4A.
• Tsurushima H, Yuan X, Dillehay LE et al. Radioresponsive tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene therapy for malignant brain tumors. Cancer Gene Ther. 2007-08-01 [PMID: 17541421] (Flow Cytometry Control, Human)
  
  Details:
  DR4 NT TRAIL-R1 (IMG-141A). Flow (intracellular): Human malignant glioma (U251 & U87) cell lines exposed to varying times of radiation, Fig 4.
• Lee SH, Kim YK, Kim CS et al. E2 of hepatitis C virus inhibits apoptosis. J Immunol. 2005-12-15 [PMID: 16339562]
• Kroll TM, Bommiasamy H, Boissy RE et al. 4-Tertiary butyl phenol exposure sensitizes human melanocytes to dendritic cell-mediated killing: relevance to vitiligo. J Invest Dermatol. 2005-04-01 [PMID: 15816839] (FLOW)
• Ren YG, Wagner KW, Knee DA et al. Differential regulation of the TRAIL death receptors DR4 and DR5 by the signal recognition particle. Mol Biol Cell. 2004-11-01 [PMID: 15356269]
• Liu X, Yue P, Khuri FR, Sun SY. p53 upregulates death receptor 4 expression through an intronic p53 binding site. Cancer Res. 2004-08-01 [PMID: 15289308]
• Shigeno M, Nakao K, Ichikawa T et al. Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation. Oncogene. 2003-03-20 [PMID: 12642868]
• Chen X, Kandasamy K, Srivastava RK. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling. Cancer Res. 2003-03-01 [PMID: 12615723]
• Guan B, Yue P, Lotan R, Sun SY. Evidence that the human death receptor 4 is regulated by activator protein 1. Oncogene. 2002-05-09 [PMID: 12082627]
• Bretz JD, Mezosi E, Giordano TJ et al. Inflammatory cytokine regulation of TRAIL-mediated apoptosis in thyroid epithelial cells. Cell Death Differ. 2002-03-01 [PMID: 11859410]
• Lu G, Janjic BM, Janjic J et al. Innate direct anticancer effector function of human immature dendritic cells. II. Role of TNF, lymphotoxin-alpha(1)beta(2), Fas ligand, and TNF-related apoptosis-inducing ligand. J Immunol. 2002-02-15 [PMID: 11823516]
• Krishnamoorthy B, Darnay B, Aggarwal B et al. Glioma cells deficient in urokinase plaminogen activator receptor expression are susceptible to tumor necrosis factor-alpha-related apoptosis-inducing ligand-induced apoptosis. Clin Cancer Res. 2001-12-01 [PMID: 11751520]
• Sridhar S, Ali AA, Liang Y et al. Differential expression of members of the tumor necrosis factor alpha-related apoptosis-inducing ligand pathway in prostate cancer cells. Cancer Res. 2001-10-01 [PMID: 11585752]

Bioinformatics

• Gene Symbol: TNFRSF10A
• Uniprot:
  • O00220(Human)